Skip to main content
NCBI home page
Elsevier - PMC COVID-19 Collection logoLink to Elsevier - PMC COVID-19 Collection
. 2004 Feb 9;161(2):429–437. doi: 10.1016/0042-6822(87)90136-X

Reduced mouse neurovirulence of poliovirus type 2 lansing antigenic variants selected with monoclonal antibodies

Nicola La Monica ∗, William J Klipsky †, Vincent R Racaniello ∗,1
PMCID: PMC7131194  PMID: 2825415

Abstract

The Lansing strain of poliovirus type 2 is a mouse-adapted virus that induces a fatal paralytic disease in mice after intracerebral inoculation. Our previous results indicated that the mouse-adapted phenotype maps to the Lansing viral capsid. To further define regions of the capsid that are specifically involved in the infection of mice, antigenic variants resistant to neutralization with monoclonal antibodies were selected, and their mouse neurovirulence was studied. The monoclonal antibodies used were directed against antigenic site 1, an immunodominant loop of capsid polypeptide VP1 located on the virion surface. Ten of twenty-two variants selected had lower intracerebral neurovirulence in mice when compared to the parental virus. Four of the ten antigenic variants with reduced neurovirulence were temperature sensitive (ts) for replication in HeLa cells, while the remaining six variants replicated in HeLa cells as well as the parent virus. Two ts+ variants that were studied had a reduced ability to replicate in the mouse brain. There was no difference in the histopathology and pattern of involvement in the central nervous system of one variant compared to the parent virus. In three variants, reduction of neurovirulence correlated with specific amino acid substitutions at positions 100 and 101 of VP1, located within antigenic site 1. The is phenotype in three variants was associated with a single amino acid deletion at position 105. Virus recovered from the brain of paralyzed mice that had been inoculated with the antigenic variants was characterized to identify the virus causing disease. In most cases, brain isolates resembled the inoculated virus in neurovirulence and amino acid sequence at the antigenic site. Virus recovered from brains of paralyzed mice that had been inoculated with the is variants was either ts+ or cold sensitive, and had become more neurovirulent. These results suggest that specific amino acid changes within an antigenic site on the virion surface may result in reduction of mouse neurovirulence without affecting viral replication in cultured cells

References

  1. Dalziel R.G., Lampert P.W., Talbot P.J., Buchmeier M.J. Site specific alteration of murine hepatitis virus type 4 glycoprotein E-2 results in reduced neurovirulence. J. Virol. 1986;59:463–471. doi: 10.1128/jvi.59.2.463-471.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Dietzschold B., Wunner W.H., Wiktor T.J., Lopes A.D., Lafon M., Smith C.L., Koprowsky H. Vol. 80. 1985. Characterization of an antigenic determinant of the glycoprotein that correlates with pathogenicity of rabies virus; pp. 70–74. (Proc. Natl. Acad. Sci. USA). [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Doll S.C., Johnson T.C. Neuropeptide-induced hypothermia and the course of central nervous system disease mediated by temperature sensitive mutants of vesicular stomatitis virus. J. Virol. 1985;55:583–587. doi: 10.1128/jvi.55.3.583-587.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Evans D.M.A., Dunn G., Minor P.D., Schild G.C., Cann A.J., Stanway G., Almond J.W., Currey K., Maizel J.V. Increased neurovirulence associated with a single nucleotide change in a non-coding region of the Sabin type 3 poliovaccine genome. Nature (London) 1985;314:548–550. doi: 10.1038/314548a0. [DOI] [PubMed] [Google Scholar]
  5. Evans D.M.A., Minor P.D., Schild G.C., Almond J.W. Critical role of an eight-amino acid sequence of VP1 in neutralization of poliovirus type 3. Nature (London) 1983;304:459–462. doi: 10.1038/304459a0. [DOI] [PubMed] [Google Scholar]
  6. Fleming J.0., Trousdale M.D., El-Zaatari F.A.K., Stohlman S.A., Weiner L.P. Pathogenicity of antigenic variants of murine coronavirus JHM selected with monoclonal antibodies. J. Virol. 1986;58:869–875. doi: 10.1128/jvi.58.3.869-875.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Hogle J.M., Chow M., Filman D.J. Three-dimensional structure of poliovirus at 2.9 A resolution. Science. 1985;229:1358–1365. doi: 10.1126/science.2994218. [DOI] [PubMed] [Google Scholar]
  8. Jubelt B., Meagher J.B. Poliovirus infection of cyclophosphamide-treated mice results in persistence and late paralysis. I. Clinical, pathologic, and immunologic studies. Neurology. 1984;34:486–493. doi: 10.1212/wnl.34.4.486. [DOI] [PubMed] [Google Scholar]
  9. Jubelt B., Narayan 0., Johnson R.T. Pathogenesis of human poliovirus infection in mice. I. Clinical and pathological studies. J. Neuropathol. Exp. Neurol. 1980;39:138–148. doi: 10.1097/00005072-198003000-00003. [DOI] [PubMed] [Google Scholar]
  10. La Monica N., Meriam C., Racaniello V.R. Mapping of sequences required for mouse neurovirulence of poliovirus type 2 Lansing. J. Virol. 1986;57:515–525. doi: 10.1128/jvi.57.2.515-525.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Löve A., Rydbeck R., Kristensson K., Örvell C., Norby E. Hemagglutinin-neuraminidase glycoprotein as a determinant of pathogenicity in mumps virus hamster encephalitis: Analysis of mutants selected with monoclonal antibodies. J. Virol. 1985;53:67–74. doi: 10.1128/jvi.53.1.67-74.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Minor P.D., Ferguson M., Evans D.M.A., Almond J.W., Icenogle J.P. Antigenic structure of poliovirus serotypes 1, 2, and 3. J. Gen. Virol. 1986;67:1283–1291. doi: 10.1099/0022-1317-67-7-1283. [DOI] [PubMed] [Google Scholar]
  13. Racaniello V.R. Poliovirus type 2 produced from cloned cDNA is infectious in mice. Virus Res. 1984;1:669–675. [Google Scholar]
  14. Reed L.J., Muench H. A simple method of estimating fifty percent end points. Amer. J. Hyg. 1938;27:493–497. [Google Scholar]
  15. Spriggs D.R., Fields B.N. Attenuated reovirus type 3 strains generated by selection of haemagglutinin antigenic variants. Nature (London) 1982;297:68–70. doi: 10.1038/297068a0. [DOI] [PubMed] [Google Scholar]

Articles from Virology are provided here courtesy of Elsevier

RESOURCES